Can You Take Ozempic While Pregnant? The Short Answer and the Clinical Reasoning

Key Takeaways

• No. Ozempic (semaglutide) is not recommended during pregnancy. The FDA label advises discontinuing the medication at least 2 months before a planned pregnancy.
• The 2-month washout reflects semaglutide's long half-life of about 7 days, which means it takes roughly 5 to 6 weeks to fully clear the body.
• Animal studies have shown adverse effects on fetal development, including reduced fetal weight and skeletal abnormalities at higher doses (Andersen et al., Reprod Toxicol 2018).
• Pregnancy itself increases the body's caloric needs. Weight loss during pregnancy is generally not recommended for women without specific medical indications.
• If you become pregnant while taking Ozempic, contact your provider immediately to discuss next steps. Do not stop abruptly without guidance.

Direct answer (40-60 words)

No. You should not take Ozempic while pregnant. The FDA recommends discontinuing semaglutide at least 2 months before a planned pregnancy because of its 7-day half-life and animal data showing potential harm to fetal development. If you become pregnant unexpectedly while on Ozempic, contact your provider immediately for guidance.

Table of contents

1. The 30-second answer
2. What the FDA label says
3. The 2-month washout: where the timeline comes from
4. Animal study findings
5. Human pregnancy registry data
6. If you become pregnant unexpectedly
7. Trying to conceive: a planning guide
8. Postpartum and breastfeeding considerations
9. Weight management during pregnancy
10. FAQ
11. Sources
12. Footer disclaimers

What the FDA label says

The FDA-approved prescribing information for Ozempic (semaglutide) includes specific guidance on use during pregnancy.

The label states that semaglutide should be discontinued at least 2 months before a planned pregnancy "because of the long washout period for semaglutide." The label categorizes the medication's pregnancy risk as based on animal data alone, since human data are limited.

The same recommendation applies to Wegovy (semaglutide 2.4 mg) and Rybelsus (oral semaglutide). All three contain the same active ingredient and follow the same washout guidance.

For tirzepatide (Mounjaro and Zepbound), the FDA label includes similar pregnancy precautions and recommends discontinuation 1 to 2 months before pregnancy due to its 5-day half-life.

The recommendation is conservative because the human safety data are limited. Pregnant women have historically been excluded from drug trials, including the GLP-1 medication trials. As a result, providers err on the side of caution and treat the medication as contraindicated during pregnancy.

The 2-month washout: where the timeline comes from

Semaglutide has a half-life of approximately 7 days. The standard pharmacokinetic rule is that a drug is considered fully cleared after 5 half-lives (about 35 days for semaglutide, or 5 weeks).

The FDA's 2-month washout adds an extra safety margin. The reasoning:

• 5 half-lives clears about 97% of the drug.
• 6 half-lives clears about 98.4%.
• 7 to 8 half-lives clears 99% or more.
• 2 months covers approximately 8 to 9 half-lives, providing high confidence the drug is fully cleared.

For tirzepatide, the half-life is about 5 days, so 5 half-lives is 25 days. The 1 to 2 month recommendation provides similar safety margin.

For comparison, here are the washout periods for related medications:

Medication	Half-life	Recommended washout before conception
Ozempic / Wegovy / Rybelsus (semaglutide)	7 days	2 months
Mounjaro / Zepbound (tirzepatide)	5 days	1 to 2 months
Saxenda (liraglutide)	13 hours	1 to 2 weeks

The shorter half-life of liraglutide is one reason it has occasionally been considered for women planning pregnancy who can't tolerate a long washout, though even liraglutide is not recommended during pregnancy itself.

Animal study findings

Pre-clinical animal studies are the primary safety data for semaglutide in pregnancy. The findings:

Rats (Andersen et al., Reproductive Toxicology, 2018): Pregnant rats exposed to semaglutide at doses several times the human equivalent showed reduced maternal weight gain, increased early embryonic loss, and reduced fetal weight. Some skeletal abnormalities were observed in offspring.

Rabbits: Similar findings of reduced fetal weight and increased structural abnormalities at higher exposure levels.

Cynomolgus monkeys: Reduced fetal growth was observed in studies with semaglutide exposure during gestation.

It's important to interpret animal data carefully. The doses used in these studies are typically several times higher than human therapeutic exposure, and animal models don't always translate directly to human outcomes. The FDA's recommendation is conservative based on consistent signals across species rather than a known mechanism of human harm.

The mechanism of concern is that semaglutide may affect maternal nutrition (through suppressed appetite) and possibly cross the placenta to affect fetal nutrient delivery. Both pathways could contribute to reduced fetal growth even if the medication itself is not directly teratogenic.

Human pregnancy registry data

Novo Nordisk maintains a pregnancy registry for patients exposed to semaglutide during pregnancy or in the months before conception. Registry data are limited but growing.

A 2023 update from the Novo Nordisk pregnancy surveillance program reported on approximately 165 documented pregnancies with semaglutide exposure (most in the first trimester). The findings:

• Rate of major congenital malformations was approximately 5.4%, compared with a 3 to 4% baseline rate in the general population. The difference was not statistically significant given the small sample size.
• No specific pattern of birth defects was identified.
• Rate of spontaneous abortion was within the expected baseline range.

These data are reassuring but not definitive. The sample size is too small to detect rare adverse events, and the registry depends on voluntary reporting.

A 2024 cohort study published in JAMA Internal Medicine (Cesta et al.) examined approximately 938 pregnancies with first-trimester GLP-1 exposure across multiple Nordic countries. The study found no significant increase in major congenital malformations compared with insulin-exposed pregnancies. The authors noted that GLP-1 exposure during early pregnancy was unlikely to be a major teratogen, but recommended continuing the FDA's washout guidance until larger datasets are available.

If you become pregnant unexpectedly

If you become pregnant while taking Ozempic, here's the recommended sequence:

1. Don't panic. Limited human data so far do not suggest a high risk of major birth defects from first-trimester exposure. The unknowns are real but the available evidence is reassuring.

2. Contact your prescribing provider promptly. They'll typically recommend stopping Ozempic immediately. Don't take any further doses without confirming with the provider.

3. Schedule an obstetric appointment. A confirmed pregnancy with a recent GLP-1 exposure should be evaluated by an OB-GYN or maternal-fetal medicine specialist. They may recommend additional ultrasound monitoring during the pregnancy.

4. Report the exposure to the manufacturer's pregnancy registry. Novo Nordisk has a confidential registry that tracks outcomes. Reporting helps build the dataset for future patients. Your provider can submit on your behalf.

5. Continue routine prenatal care. Ozempic exposure does not typically change recommended prenatal care. Standard ultrasound, lab, and screening protocols still apply.

6. Discuss diabetes management if applicable. If you took Ozempic for type 2 diabetes, your provider will help you transition to pregnancy-safe diabetes medications, typically insulin or metformin. Both have extensive safety data in pregnancy.

Trying to conceive: a planning guide

For women planning pregnancy who currently take Ozempic, the standard timeline:

8 to 12 weeks before trying to conceive:

• Discuss the plan with your provider.
• Stop Ozempic.
• Switch to alternative diabetes management if needed (metformin, insulin).
• Begin prenatal vitamins with folic acid.

4 to 6 weeks after stopping:

• Most patients will see weight regain begin around this time as appetite returns.
• This is expected and not a sign of failure. The medication's appetite-suppression effect is gone, and the body's set point reasserts.

8 weeks after stopping (start of conception window):

• The medication is considered fully cleared.
• Active conception attempts can begin.

During pregnancy:

• Routine prenatal care.
• No GLP-1 medications.
• Diabetes management with insulin or metformin if applicable.
• Healthy weight gain per ACOG guidelines (typically 25 to 35 pounds for normal-BMI patients, less for higher-BMI patients).

Postpartum:

• Discuss with your provider when GLP-1 medications can be restarted.
• Breastfeeding considerations apply (see next section).

This timeline gets adjusted based on individual circumstances. Patients with type 2 diabetes need close glucose monitoring before, during, and after pregnancy, with HbA1c ideally below 6.5% before conception per ACOG guidance.

Postpartum and breastfeeding considerations

The FDA label for Ozempic states that the medication should not be used during breastfeeding because semaglutide may pass into breast milk, with unknown effects on the breastfed infant.

Animal studies show small amounts of semaglutide in breast milk, with limited absorption by nursing offspring. Whether human infants would absorb semaglutide from breast milk through the GI tract is unknown but considered unlikely given the molecule's size.

The conservative recommendation: avoid semaglutide while breastfeeding. Most providers advise waiting until weaning is complete before restarting Ozempic or Wegovy.

Some patients balance this against the benefits of postpartum weight management. Decisions are individual and should involve a provider familiar with both lactation and weight medicine.

For women with type 2 diabetes who need treatment during breastfeeding, metformin and insulin are both compatible with lactation and have extensive safety data.

Weight management during pregnancy

Pregnancy requires additional calories, not fewer. The American College of Obstetricians and Gynecologists (ACOG) recommends:

• Underweight (BMI under 18.5): Gain 28 to 40 pounds during pregnancy.
• Normal weight (BMI 18.5 to 24.9): Gain 25 to 35 pounds.
• Overweight (BMI 25 to 29.9): Gain 15 to 25 pounds.
• Obese (BMI 30+): Gain 11 to 20 pounds.

Active weight loss during pregnancy is generally not recommended even for women with obesity, because it can compromise fetal nutrition and development. The exception is bariatric-surgery patients in the early postoperative period, where specialized obstetric care is involved.

For women with obesity who are planning pregnancy, the recommended approach is to optimize weight before conception. This is the window when GLP-1 medications can be useful, with appropriate washout before trying to conceive.

After delivery, GLP-1 medications can be considered once breastfeeding has ended and any postpartum weight retention has been evaluated. For women planning multiple pregnancies, the cycle of optimize-before-conceive-then-stop is common.

What about gestational diabetes?

Gestational diabetes (GDM) is high blood sugar diagnosed during pregnancy. It's typically managed with diet, exercise, and if needed, insulin or metformin. Ozempic and other GLP-1 medications are not approved for GDM and are not recommended during pregnancy.

Insulin is the gold-standard medication for GDM not controlled by diet alone. Metformin is also commonly used and has decades of pregnancy safety data.

After delivery, women who had GDM are at increased risk of developing type 2 diabetes. Postpartum follow-up with screening at 6 to 12 weeks postpartum is recommended. If type 2 diabetes is diagnosed, GLP-1 medications can be considered (after breastfeeding ends) as part of long-term management.

What about IVF and fertility treatments?

Some women take Ozempic for type 2 diabetes or PCOS-related weight management while undergoing fertility evaluation. The FDA washout guidance applies: stop semaglutide at least 2 months before active conception attempts, including IVF.

For women undergoing IVF, the washout timing should account for the fact that ovarian stimulation cycles begin before embryo transfer. Working with both the reproductive endocrinologist and the prescribing provider on timing is important.

There is no specific evidence that semaglutide affects egg quality, sperm quality, or embryonic development at the embryo level. The concern is exposure during early pregnancy, after implantation.

FAQ

Can you take Ozempic while pregnant? No. The FDA does not recommend Ozempic during pregnancy. Stop the medication at least 2 months before a planned pregnancy, and contact your provider immediately if you become pregnant unexpectedly while on Ozempic.

How long should I stop Ozempic before trying to get pregnant? At least 2 months. Ozempic has a 7-day half-life, so it takes roughly 5 to 6 weeks to fully clear the body. The 2-month recommendation provides additional safety margin.

What happens if I find out I'm pregnant while on Ozempic? Stop the medication and contact your provider promptly. Schedule a prenatal appointment. The current limited data don't show a high risk of birth defects, but additional monitoring may be recommended.

Does Ozempic cause birth defects? Animal studies show reduced fetal weight and skeletal abnormalities at higher doses. Limited human registry data have not shown a clear pattern of birth defects, but the dataset is small. The FDA's conservative recommendation is to avoid the medication in pregnancy.

Can Ozempic affect fertility or make it harder to get pregnant? Ozempic can improve fertility in some women, particularly those with PCOS or insulin resistance, by improving ovulation. However, the medication itself should be discontinued before active conception attempts due to pregnancy concerns.

Is Ozempic safe while breastfeeding? The FDA label recommends against breastfeeding while on Ozempic because semaglutide may pass into breast milk with unknown effects on the infant. Most providers recommend waiting until breastfeeding ends before restarting.

What can I take instead of Ozempic during pregnancy if I have diabetes? Insulin and metformin are both considered safe in pregnancy and have extensive safety data. Your provider will help transition you to pregnancy-appropriate diabetes management.

Will I gain back the weight if I stop Ozempic to get pregnant? Some weight regain is common when GLP-1 medications are discontinued, typically beginning 4 to 8 weeks after stopping. During pregnancy, healthy weight gain is expected and recommended (typically 11 to 35 pounds depending on starting BMI).

Can I take a smaller Ozempic dose during pregnancy? No. There is no recommended pregnancy dose. The medication should be discontinued, not reduced.

Is compounded semaglutide safer than Ozempic during pregnancy? No. Both contain semaglutide and pose the same theoretical risks. The same washout recommendations apply.

What about Wegovy and Mounjaro during pregnancy? The same recommendations apply. Wegovy contains semaglutide; Mounjaro contains tirzepatide. Both should be stopped before pregnancy, with similar washout periods (2 months for semaglutide, 1 to 2 months for tirzepatide).

Can I take Ozempic if I'm trying to lose weight before getting pregnant? Yes, with the understanding that you'll need to stop at least 2 months before active conception attempts. Many women use GLP-1 medications during the preconception planning window, then transition to non-medication weight management during pregnancy.

Sources

1. Ozempic (semaglutide) prescribing information. Novo Nordisk; rev. 2024.
2. Wegovy (semaglutide) prescribing information. Novo Nordisk; rev. 2024.
3. Andersen LF, Knudsen LB, Hare KJ, et al. Reproductive and developmental toxicity of semaglutide. Reprod Toxicol. 2018;79:31-39.
4. Cesta CE, Cohen JM, Pazzagli L, et al. Antidiabetic medication use in early pregnancy and major congenital malformations. JAMA Intern Med. 2024;184:144-152.
5. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 230: Obesity in Pregnancy. Obstet Gynecol. 2021;137:e128-e144.
6. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 548: Weight gain during pregnancy. Obstet Gynecol. 2013;121:210-212.
7. American Diabetes Association. Standards of Medical Care in Diabetes 2024: Management of Diabetes in Pregnancy. Diabetes Care. 2024;47(Suppl 1):S282-S294.
8. Mounjaro (tirzepatide) prescribing information. Eli Lilly; rev. 2024.
9. Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics initiative on gestational diabetes mellitus. Int J Gynaecol Obstet. 2015;131(Suppl 3):S173-S211.
10. Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Saf. 2007;6:191-198.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Saxenda is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.